Financial Snapshot

Revenue
$929.2M
TTM
Gross Margin
91.51%
TTM
Net Earnings
$128.5M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
229.19%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$577.2M
Q3 2024
Cash
Q3 2024
P/E
22.23
Nov 29, 2024 EST
Free Cash Flow
$173.6M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 1999 1998 1997
Revenue $726.4M $517.2M $484.1M $441.8M $339.1M $223.8M $124.9M $17.33M $61.00K $120.0K $1.145M $4.907M $2.067M $42.14M $6.400M $1.600M $7.600M $8.100M $11.00M $4.600M $7.400M $6.300M $3.700M $2.200M $1.400M $800.0K
YoY Change 40.45% 6.83% 9.6% 30.28% 51.5% 79.19% 620.68% 28311.48% -49.17% -89.52% -76.67% 137.4% -95.09% 558.36% 300.0% -78.95% -6.17% -26.36% 139.13% -37.84% 17.46% 70.27% -13.95% 57.14% 75.0% 100.0%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 1999 1998 1997
Revenue $726.4M $517.2M $484.1M $441.8M $339.1M $223.8M $124.9M $17.33M $61.00K $120.0K $1.145M $4.907M $2.067M $42.14M $6.400M $1.600M $7.600M $8.100M $11.00M $4.600M $7.400M $6.300M $3.700M $2.200M $1.400M $800.0K
Cost Of Revenue $41.64M $10.17M $10.84M $10.21M $11.34M $12.38M $9.077M $3.075M $2.500M $0.00
Gross Profit $684.8M $507.1M $473.3M $431.5M $327.7M $211.4M $115.8M $14.25M -$2.400M $100.0K
Gross Profit Margin 94.27% 98.03% 97.76% 97.69% 96.65% 94.47% 92.73% 82.23% -3934.43% 83.33%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 1999 1998 1997
Selling, General & Admin $406.6M $369.1M $396.0M $388.7M $325.6M $265.8M $255.1M $186.5M $88.30M $32.70M $12.70M $7.000M $5.900M $6.500M $9.000M $9.700M $12.30M $11.30M $10.20M $6.800M $4.200M $4.000M $5.900M $2.600M $2.500M $1.800M
YoY Change 10.15% -6.8% 1.9% 19.35% 22.53% 4.19% 36.79% 111.15% 170.04% 157.48% 81.43% 18.64% -9.23% -27.78% -7.22% -21.14% 8.85% 10.78% 50.0% 61.9% 5.0% -32.2% 0.0% 4.0% 38.89% 800.0%
% of Gross Profit 59.37% 72.79% 83.67% 90.06% 99.36% 125.7% 220.22% 1308.28% 32700.0%
Research & Development $351.6M $361.6M $239.4M $319.1M $240.4M $187.2M $149.2M $99.28M $73.87M $60.60M $26.72M $18.79M $17.31M $20.58M $41.60M $56.80M $57.90M $49.40M $30.30M $23.90M $16.90M $14.90M $13.10M $7.500M $5.900M $2.300M
YoY Change -2.75% 51.02% -24.98% 32.76% 28.44% 25.45% 50.26% 34.41% 21.89% 126.79% 42.18% 8.58% -15.89% -50.53% -26.76% -1.9% 17.21% 63.04% 26.78% 41.42% 13.42% 13.74% 35.05% 27.12% 156.52% 475.0%
% of Gross Profit 51.35% 71.31% 50.58% 73.95% 73.35% 88.52% 128.81% 696.63% 60602.0%
Depreciation & Amortization $1.500M $2.000M $2.200M $1.500M $1.300M $1.500M $1.200M $843.0K $647.0K $206.0K $79.00K $109.0K $285.0K $607.0K $1.110M $1.040M $1.070M $850.0K $1.030M $1.310M $1.340M $1.400M $1.360M $790.0K $510.0K $160.0K
YoY Change -25.0% -9.09% 46.67% 15.38% -13.33% 25.0% 42.35% 30.29% 214.08% 160.76% -27.52% -61.75% -53.05% -45.32% 6.73% -2.8% 25.88% -17.48% -21.37% -2.24% -4.29% 2.94% 54.9% 218.75%
% of Gross Profit 0.22% 0.39% 0.46% 0.35% 0.4% 0.71% 1.04% 5.91% 206.0%
Operating Expenses $758.2M $730.7M $635.4M $707.8M $566.0M $452.9M $404.3M $285.7M $164.7M $93.35M $39.44M $25.79M $24.92M $27.04M $50.60M $66.40M $70.20M $60.80M $40.60M $30.70M $21.10M $18.90M $19.00M $10.10M $8.300M $4.100M
YoY Change 3.77% 14.99% -10.22% 25.05% 24.97% 12.04% 41.48% 73.52% 76.4% 136.68% 52.92% 3.51% -7.85% -46.56% -23.8% -5.41% 15.46% 49.75% 32.25% 45.5% 11.64% -0.53% 21.79% 21.69% 102.44% 583.33%
Operating Profit -$73.38M -$223.6M -$170.4M -$286.6M -$246.5M -$247.4M -$292.4M -$272.8M -$164.6M -$93.23M -$38.30M -$20.89M -$22.85M $15.09M
YoY Change -67.18% 31.19% -40.53% 16.24% -0.36% -15.38% 7.18% 65.73% 76.57% 143.44% 83.36% -8.6% -251.4%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 1999 1998 1997
Interest Expense $17.23M $6.610M $591.0K $6.610M $11.17M $5.348M $4.126M $2.763M $499.0K $755.0K $349.0K $37.00K $87.00K $0.00 $300.0K $2.700M $6.300M $4.000M $1.700M $200.0K -$400.0K -$200.0K $900.0K $400.0K $500.0K $200.0K
YoY Change 160.73% 1018.44% -91.06% -40.8% 108.77% 29.62% 49.33% 453.71% -33.91% 116.33% 843.24% -57.47% -100.0% -88.89% -57.14% 57.5% 135.29% 750.0% -150.0% 100.0% -122.22% -18.18% -20.0% 150.0%
% of Operating Profit 0.0%
Other Income/Expense, Net $5.109M $3.542M -$2.329M -$997.0K $997.0K -$1.840M
YoY Change 44.24% -252.08% 133.6% -200.0% -154.18%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 1999 1998 1997
Pretax Income -$51.04M -$213.4M -$167.5M -$281.0M -$234.4M -$243.9M -$288.3M -$270.1M -$164.1M -$92.48M -$37.95M -$20.80M -$22.80M $15.10M -$45.10M -$64.20M -$56.40M -$45.10M -$34.10M -$25.90M -$14.10M -$12.90M -$14.40M -$7.400M -$6.400M -$3.000M
YoY Change -76.09% 27.41% -40.38% 19.88% -3.92% -15.38% 6.75% 64.55% 77.47% 143.69% 82.44% -8.77% -250.99% -133.48% -29.75% 13.83% 25.06% 32.26% 31.66% 83.69% 9.3% -10.42% 41.18% 15.63% 113.33% 1400.0%
Income Tax $10.25M $2.531M $351.0K $611.0K $876.0K $1.256M $1.119M $1.341M $330.0K $0.00 $0.00 $0.00 $17.00K $12.00K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income 0.08%
Net Earnings -$61.29M -$216.0M -$167.9M -$281.6M -$235.3M -$245.2M -$289.4M -$271.4M -$164.4M -$92.48M -$37.95M -$20.85M -$22.77M $15.14M -$45.10M -$64.20M -$56.40M -$45.00M -$34.10M -$25.90M -$14.10M -$12.90M -$14.40M -$7.400M -$6.400M -$3.000M
YoY Change -71.62% 28.66% -40.38% 19.69% -4.05% -15.28% 6.64% 65.04% 77.82% 143.69% 82.01% -8.42% -250.37% -133.57% -29.75% 13.83% 25.33% 31.96% 31.66% 83.69% 9.3% -10.42% 41.18% 15.63% 113.33% 1400.0%
Net Earnings / Revenue -8.44% -41.76% -34.67% -63.74% -69.38% -109.56% -231.71% -1565.94% -269578.69% -77062.5% -3314.24% -424.88% -1101.35% 35.93% -704.69% -4012.5% -742.11% -555.56% -310.0% -563.04% -190.54% -204.76% -389.19% -336.36% -457.14% -375.0%
Basic Earnings Per Share -$0.37 -$1.34 -$1.05 -$1.79 -$0.38 -$0.44 $0.39
Diluted Earnings Per Share -$0.37 -$1.34 -$1.046M -$1.790M -$1.599M -$1.937M -$2.361M -$2.342M -$1.634M -$951.6K -$442.2K -$0.38 -$0.44 $0.39 -$1.203M -$1.730M -$1.602M -$1.613M -$1.550M -$2.490M -$9.400M -$8.600M -$3.349M -$2.643M -$3.200M -$1.765M

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 1999 1998 1997
Cash & Short-Term Investments $438.9M $416.8M $520.7M $632.0M $697.4M $473.5M $341.3M $529.0M $215.1M $322.5M $185.8M $108.0M $31.00M $37.10M $47.10M $60.10M $126.9M $83.30M $43.00M $35.90M $27.20M $12.40M $12.20M $17.60M
YoY Change 5.29% -19.95% -17.61% -9.38% 47.29% 38.73% -35.48% 145.93% -33.3% 73.57% 72.04% 248.39% -16.44% -21.23% -21.63% -52.64% 52.34% 93.72% 19.78% 31.99% 119.35% -30.68%
Cash & Equivalents $188.7M $114.8M $147.4M $326.0M $189.7M $134.8M $69.40M $163.6M $102.1M $61.90M $11.70M $57.90M $6.900M $6.800M $18.10M $21.20M $17.00M $15.50M $9.800M $8.300M $6.300M $4.500M $3.700M $4.800M
Short-Term Investments $250.2M $302.0M $373.3M $305.9M $507.7M $338.8M $271.9M $365.4M $113.0M $260.6M $174.1M $50.10M $24.20M $30.20M $28.90M $38.90M $109.9M $67.80M $33.20M $27.60M $20.90M $8.000M $8.500M $12.80M
Other Short-Term Assets $39.09M $21.40M $23.89M $25.70M $18.60M $20.70M $8.500M $7.500M $2.200M $1.200M $1.800M $600.0K $900.0K $800.0K $1.400M $2.300M $4.400M $2.500M $17.10M $1.900M $1.100M $800.0K $400.0K $600.0K
YoY Change 82.69% -10.44% -7.04% 38.17% -10.14% 143.53% 13.33% 240.91% 83.33% -33.33% 200.0% -33.33% 12.5% -42.86% -39.13% -47.73% 76.0% -85.38% 800.0% 72.73% 37.5% -33.33%
Inventory $35.82M $6.636M $7.881M $9.700M $6.300M $4.100M $5.200M $4.200M
Prepaid Expenses
Receivables $98.27M $62.20M $64.37M $48.20M $35.80M $26.10M $17.30M $5.900M $0.00 $200.0K
Other Receivables $4.083M $885.0K $978.0K $2.100M $2.100M $1.700M $1.100M $1.200M $0.00 $0.00
Total Short-Term Assets $616.1M $507.9M $617.8M $717.6M $760.3M $526.1M $373.5M $547.9M $219.0M $324.6M $188.4M $108.5M $31.90M $37.80M $48.50M $62.40M $131.3M $85.80M $60.10M $37.80M $28.30M $13.30M $12.60M $18.40M
YoY Change 21.3% -17.79% -13.9% -5.62% 44.52% 40.86% -31.83% 150.18% -32.53% 72.29% 73.64% 240.13% -15.61% -22.06% -22.28% -52.48% 53.03% 42.76% 58.99% 33.57% 112.78% -31.52%
Property, Plant & Equipment $56.47M $61.59M $66.32M $56.40M $12.70M $3.300M $2.700M $3.100M $2.200M $600.0K $600.0K $0.00 $200.0K $400.0K $1.100M $2.100M $3.000M $3.500M $2.300M $2.500M $3.100M $2.400M $2.500M $2.300M
YoY Change -8.32% -7.12% 17.58% 344.09% 284.85% 22.22% -12.9% 40.91% 266.67% 0.0% -100.0% -50.0% -63.64% -47.62% -30.0% -14.29% 52.17% -8.0% -19.35% 29.17% 8.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.87M $18.28M $15.98M $7.400M $7.600M $6.700M $2.800M $3.200M $700.0K $300.0K $200.0K $0.00 $0.00 $100.0K $100.0K $200.0K $300.0K $300.0K $100.0K $0.00 $300.0K $400.0K $400.0K $400.0K
YoY Change -40.52% 14.37% 116.0% -2.63% 13.43% 139.29% -12.5% 357.14% 133.33% 50.0% -100.0% 0.0% -50.0% -33.33% 0.0% 200.0% -100.0% -25.0% 0.0%
Total Long-Term Assets $132.8M $79.88M $82.30M $65.00M $22.90M $14.10M $11.00M $13.30M $2.900M $900.0K $700.0K $100.0K $200.0K $600.0K $1.200M $2.300M $3.300M $3.700M $2.400M $2.600M $3.400M $2.700M $2.900M $2.700M
YoY Change 66.3% -2.95% 26.61% 183.84% 62.41% 28.18% -17.29% 358.62% 222.22% 28.57% 600.0% -50.0% -66.67% -50.0% -47.83% -30.3% -10.81% 54.17% -7.69% -23.53% 25.93% 7.41%
Total Assets $749.0M $587.8M $700.1M $782.6M $783.2M $540.2M $384.5M $561.2M $221.9M $325.5M $189.1M $108.6M $32.10M $38.40M $49.70M $64.70M $134.6M $89.50M $62.50M $40.40M $31.70M $16.00M $15.50M $21.10M
YoY Change
Accounts Payable $17.54M $12.75M $6.876M $8.500M $7.200M $3.200M $8.800M $3.900M $1.700M $2.000M $400.0K $1.400M $2.000M $2.000M $2.900M $2.300M $2.600M $3.400M $2.100M $2.200M $1.500M $1.100M $200.0K $300.0K
YoY Change 37.64% 85.37% -19.11% 18.06% 125.0% -63.64% 125.64% 129.41% -15.0% 400.0% -71.43% -30.0% 0.0% -31.03% 26.09% -11.54% -23.53% 61.9% -4.55% 46.67% 36.36% -33.33%
Accrued Expenses $236.7M $112.9M $89.19M $97.50M $67.60M $56.40M $40.20M $36.00M $20.20M $13.80M $6.600M $4.100M $3.500M $3.200M $5.400M $7.500M $15.00M $13.50M $15.30M $3.700M $2.100M $1.700M $700.0K $800.0K
YoY Change 109.69% 26.56% -8.52% 44.23% 19.86% 40.3% 11.67% 78.22% 46.38% 109.09% 60.98% 17.14% 9.38% -40.74% -28.0% -50.0% 11.11% -11.76% 313.51% 76.19% 23.53% -12.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $100.0K $400.0K $800.0K $1.000M $1.000M $900.0K $1.500M $3.200M $3.000M $600.0K $100.0K
YoY Change -100.0% -75.0% -50.0% -20.0% 0.0% 11.11% -40.0% -53.13% 6.67% 500.0%
Total Short-Term Liabilities $254.3M $125.6M $96.07M $106.0M $74.80M $59.60M $49.00M $42.60M $21.90M $15.80M $7.000M $5.900M $6.200M $6.000M $14.70M $11.10M $19.30M $20.50M $21.70M $8.600M $8.200M $6.200M $1.900M $1.400M
YoY Change 102.38% 30.77% -9.37% 41.71% 25.5% 21.63% 15.02% 94.52% 38.61% 125.71% 18.64% -4.84% 3.33% -59.18% 32.43% -42.49% -5.85% -5.53% 152.33% 4.88% 32.26% 35.71%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $100.0K $400.0K $1.200M $1.400M $900.0K $1.000M $1.600M $3.500M $4.400M $3.400M
YoY Change -100.0% -75.0% -66.67% -14.29% 55.56% -10.0% -37.5% -54.29% 29.41%
Other Long-Term Liabilities $62.95M $61.77M $63.16M $49.60M $9.200M $1.600M $200.0K $200.0K $200.0K $100.0K $0.00 $17.70M $2.600M $2.700M $22.80M $200.0K $200.0K $500.0K $500.0K $0.00
YoY Change 1.91% -2.2% 27.34% 439.13% 475.0% 700.0% 0.0% 0.0% 100.0% -100.0% 580.77% -3.7% -88.16% 11300.0% 0.0% -60.0% 0.0%
Total Long-Term Liabilities $62.95M $61.77M $63.16M $49.60M $9.200M $1.600M $200.0K $200.0K $200.0K $100.0K $0.00 $17.70M $2.600M $2.700M $22.90M $600.0K $1.400M $1.900M $1.400M $1.000M $1.600M $3.500M $4.400M $3.400M
YoY Change 1.91% -2.2% 27.34% 439.13% 475.0% 700.0% 0.0% 0.0% 100.0% -100.0% 580.77% -3.7% -88.21% 3716.67% -57.14% -26.32% 35.71% 40.0% -37.5% -54.29% 29.41%
Total Liabilities $317.2M $187.4M $159.2M $155.6M $84.00M $61.10M $49.20M $42.70M $22.10M $16.00M $7.000M $23.60M $8.800M $8.700M $37.60M $11.70M $20.70M $22.40M $23.10M $9.700M $9.900M $9.600M $6.300M $4.800M
YoY Change 69.27% 17.69% 2.33% 85.24% 37.48% 24.19% 15.22% 93.21% 38.13% 128.57% -70.34% 168.18% 1.15% -76.86% 221.37% -43.48% -7.59% -3.03% 138.14% -2.02% 3.13% 31.25%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 1999 1998 1997
Basic Shares Outstanding 163.8K 161.7K 160.5K 157.3K 55.12M shares 52.18M shares 38.59M shares
Diluted Shares Outstanding 163.8K 161.7K 160.5K 157.3K 55.12M shares 52.18M shares 38.72M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $2.8569 Billion

About ACADIA PHARMACEUTICALS INC

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. The company is headquartered in San Diego, California and currently employs 620 full-time employees. The company went IPO on 2004-05-27. The firm is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. The company has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.

Industry: Pharmaceutical Preparations Peers: AMICUS THERAPEUTICS, INC. ARROWHEAD PHARMACEUTICALS, INC. Beam Therapeutics Inc. BIOCRYST PHARMACEUTICALS INC Denali Therapeutics Inc. INSMED Inc Relay Therapeutics, Inc. Ultragenyx Pharmaceutical Inc. Vir Biotechnology, Inc.